Rentschler with double-digit investment in Germany

Rentschler Biopharma SE, a spezialised manufacturing organization (CDMO) for biopharmaceuticals, including advanced therapy medicinal products (ATMPs), announced the construction of a new state-of-the-art buffer media station at its company headquarters in Laupheim. The new facility aims to further increase production efficiency and modernize the site, ensuring that the evolving needs of clients are anticipated and fully met. The investment is the largest that Rentschler has ever made at its headquarters and, according to industry experts familiar with the matter, is expected to be in the high double-digit million euro range.

“This investment underscores our commitment to the long-term development of our Laupheim site, a key part of Germany’s biotechnology landscape”, said Benedikt von Braunmühl, Chief Executive Officer of Rentschler Biopharma. “This expansion will strengthen our competitive position in one of the world’s fastest-growing industries. As a company with 150 years of tradition, Rentschler Biopharma has always embraced forward-looking, strategic planning, enabling us to grow sustainably as an independent family-owned company.”

The governmental support for a German national pharmaceutical strategy is also an important signal for the industry as a whole, the company stated. The state-of-the-art, four-story buffer media station, covering 34,000 square meters, is set to be operational by 2028. The new facility will be seamlessly integrated with the existing infrastructure, offering faster and more efficient processes, as well as ergonomically designed workstations, providing an optimal working environment for employees. The new building, along with all technical systems, will run highly automated, and, through its state-of-the-art equipment, “support Rentschler Biopharma’s environmental and sustainability goals”, the CEO added.

Von Braunmühl just recently stated in an interview with European Biotech News that there is space for spezialised CDMOs, even as more and more large companies are merging. More about the positioning and strategy of Rentschler in this space can be found on page 28 in the CDMO-Special of Magazine issue 3/24:

https://european-biotechnology.com/wp-content/uploads/2024/09/EB324_Special.pdf